Lexeo Therapeutics Reports Q2 2026 Financial Results

What Happened
Lexeo Therapeutics, Inc. announced business highlights and reported its financial results for the three and six months ended June 30, 2026 via a press release issued on August 12, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K. On the same date the company also posted an updated corporate presentation on its website, provided as Exhibit 99.2.

Key Details

• Form 8-K filed and dated August 12, 2026, covering results for the periods ended June 30, 2026.
• Exhibit 99.1: Press release announcing business highlights and quarterly/half‑year financial results.
• Exhibit 99.2: Updated corporate presentation (dated August 12, 2026) to be used in investor and analyst meetings.
• Form 8-K signed by R. Nolan Townsend, Chief Executive Officer.

Why It Matters
This filing signals that Lexeo has released its latest quarterly results and investor materials; shareholders and prospective investors should review the press release and corporate presentation for specifics on revenue, earnings, cash position, guidance, and program updates. Because the 8-K itself references those exhibits rather than embedding detailed financial tables in the filing text, the exhibits are the primary source for the financial and operational detail investors will need.